James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Vale SA (VALE), Lululemon Athletica Inc. (LULU) and AbbVie Inc. (ABBV) Are 3 of Today’s Worst Stocks

AbbVie (ABBV), Lululemon Athletica (LULU) and Vale SA (VALE) led the marketwide bearish charge on Monday.

5 Big Pharma Stocks to Buy (And 2 Busts to Avoid!)

Several Big Pharma names are worthy buys right now, but a couple of pharmaceutical stocks may be best left avoided.

This Is What Amazon’s Cyber Monday Win Means for AMZN Stock

Valuation insanity aside, AMZN stock is poised to benefit from yet another successful Cyber Monday advertising campaign by spinning the day's success into much, much more.

Q3 Earnings Wrap-Up: No Matter How You Slice It, the S&P 500 Is Overvalued

The S&P 500 saw a sharp drop in third-quarter earnings. Oil's implosion gets the blame, but the energy sector shouldn't shoulder the whole blame for the market's unusually high price-earnings levels.

Hewlett-Packard: The (Old) HPQ Era Ends Unimpressively

HP (HPQ) and Hewlett Packard Enterprise (HPE) are already starting to show significant performance differences.